Campbell Alliance Launches Encuity Research Subsidiary
March 21, 2012
NEW YORK, NY – Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the launch of Encuity Research, the firm’s market research and analytics subsidiary. Michael Turner, a six-year veteran with Campbell Alliance, will serve as General Manager of Encuity Research. The company will be based in Newtown, PA.
The launch of Encuity Research immediately follows the acquisition of SDI Health’s promotional and medical audit businesses from IMS Health. The deal closed on March 20, 2012, and financial terms of the transaction were not disclosed.
According to Nader Naeymi-Rad, CEO of Campbell Alliance, “The audit businesses acquired from IMS will be combined with our existing market research and analytics service lines to create a very robust business that will drive accelerated growth for us in the market research segment. In addition, Encuity Research’s services will provide Campbell Alliance and our parent company, inVentiv Health, with new insights for clients that will enhance our ability to deliver powerful solutions.”
Encuity Research will provide a range of services to the pharmaceutical and biotech industry in five specific areas, including:
- Custom quantitative research and analytics
- Qualitative research
- Key opinion leader identification and mapping
- Message tracking including Rapid RecallSM message effectiveness studies
- Syndicated audits including the Metropolitan Area Promotional Audit, which tracks promotional activity across 15 specialty therapeutic areas; VisionCare, offering fitting and dispensing trend data on the contact lens market in the U.S. and Canada; and a wide range of SDI Health medical and promotional audits acquired from IMS Health.
As mentioned, Michael Turner will assume the role of General Manager of Encuity Research. Mr. Turner, formerly serving as a Vice President in Campbell Alliance’s Brand Management practice, brings a wealth of consulting, market research, and analytics experience to his new role. Before joining Campbell Alliance, he held consulting and leadership positions at marketRx (now Cognizant) and ZS Associates.
About this new role, Mr. Naeymi-Rad said, “Campbell Alliance is a highly growth-oriented company. As we continue to expand and to operate in new markets, new leadership opportunities become available for those within the firm who have played key roles in our growth, demonstrated great commitment, and delivered success. Michael is one of those people and I am very glad that he has agreed to lead our market research and analytics group. Michael’s promotion to take the helm of Encuity Research is well-deserved.”
For more information on Encuity Research, please visit: http://www.encuity.com.
About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Commercial Effectiveness, Pricing and Market Access, and Medical Affairs. From its locations in New York City, Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions, and any additional leverage we may incur in connection with the financing thereof, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.
Vice President, Marketing
(919) 844-7100, x7195